Affordable Access

Squalamine lactate for exudative age-related macular degeneration.

Authors
Type
Published Article
Journal
Ophthalmology clinics of North America
Publication Date
Volume
19
Issue
3
Identifiers
PMID: 16935213
Source
Medline
License
Unknown

Abstract

Squalamine lactate inhibits angiogenesis by a long-lived, intracellular mechanism of action. The drug is taken up into activated endothelial cells through caveolae, small invaginations in the cellular membrane. Subsequently, the drug binds to and "chaperones" calmodulin to an intracellular membrane compartment and blocks angiogenesis at several levels. A series of basic investigations, preclinical studies, and human clinical trials have begun to establish the proof of concept, efficacy, and safety parameters for use of squalamine lactate as a therapeutic agent for exudative age-related macular degeneration and several types of malignancies.

Statistics

Seen <100 times